| Followers | 843 |
| Posts | 122897 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Thursday, April 24, 2014 2:43:24 PM
I appreciate your stance. I just don't understand your need to repeat it regularly.
Should we all be selling [GILD] and buying your stock [ENTA]?
Do you think the posters here have any effect on the share price?
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent GILD News
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/28/2026 01:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:56:25 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/28/2026 12:53:40 PM
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel • Business Wire • 04/28/2026 12:45:00 PM
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 • Business Wire • 04/22/2026 08:05:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/17/2026 01:00:24 PM
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer • Business Wire • 04/17/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:08:03 PM
- PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access • Business Wire • 04/14/2026 04:00:00 PM
- Tempus AI Shares Gain After Expanded Partnership with Gilead • IH Market News • 04/10/2026 01:34:23 PM
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline • Business Wire • 04/07/2026 12:30:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:34:18 PM
- Gilead Extends Tender Offer to Acquire Arcellx • Business Wire • 04/01/2026 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 09:59:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:03:17 PM
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases • Business Wire • 03/23/2026 10:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:01:13 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:56:30 PM
